What Adare Pharmaceuticals does

Adare Pharmaceuticals, operating commercially as Adare Pharma Solutions, is a global technology-driven Contract Development and Manufacturing Organization (CDMO) specializing in oral solid dosage forms for the pharmaceutical industry. The company offers end-to-end integrated services spanning early-stage formulation development, clinical trial materials manufacturing, technology transfer, commercial-scale manufacturing, and packaging, serving pharmaceutical and biotech sponsors that require sophisticated drug delivery solutions for small molecules and, increasingly, peptides, proteins, and macromolecules.

The company's core technology offering is a portfolio of more than twelve proprietary, trademarked platforms — including AdvaTab® (orally disintegrating tablets), Diffucaps® (controlled release), Diffutab® (sustained release), Microcaps® (taste masking), Minitabs™ (mini-tablet multiparticulate systems), Parvulet® (pediatric and geriatric dosing), Stratμm® (injectable micro-encapsulation), Optimμm® (high-load oral microcapsules), Unisun® (intratympanic delivery), Adaptdose™ (Phase I-stable formulation), Duragran™ (controlled-release granulation), Precision Particle Fabrication™, and 3D Screen Printing. These platforms are supplemented by specialized services including nitrosamine mitigation, abuse-deterrent Category 1 testing, high-potency compound handling, and pediatric formulation development.

Adare generates revenue through B2B contract services priced via custom quotes tied to project scope, scale, and regulatory requirements, typically under multi-year agreements. Distribution is direct enterprise sales through field-based business development representatives with dedicated project management from proposal through commercialization. The company operates seven manufacturing and R&D facilities across the United States (Philadelphia, Vandalia OH, Lenexa KS, Aurora IL) and Italy (San Giuliano Milanese, Pessano con Bornago), is led by CEO Tom Sellig, has 65+ commercial products launched, and supports customers selling in 100+ countries. Capacity has been expanded through the December 2021 acquisition of Frontida BioPharm and the May 2020 acquisition of Orbis Biosciences, with a recent European packaging expansion in Milan (October 2025) and new commercial programs including Achieve Life Sciences' cytisinicline supply (2026).

Name

Adare Pharmaceuticals

Legal name

Adare Pharma Solutions

Website

https://AdarePharma.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Pharmaceutical contract manufacturing
• Oral drug delivery
• Taste masking technology
• Controlled release formulations
• CDMO services

Headquarters

HQ city

New Jersey

HQ country

Trinidad & Tobago

HQ region

Latin America

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. CDMO Contract Services: Adare Pharma Solutions generates revenue through contract development and manufacturing organization (CDMO) services, providing end-to-end integrated services from product development through commercial manufacturing and packaging for pharmaceutical companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Adare Pharma Solutions is a global technology-driven Contract Development and Manufacturing Organization (CDMO) providing end-to-end integrated services from product development through commercial manufacturing and packaging for oral dosage forms. The company offers proprietary technology platforms for taste masking, customized release, multiparticulate systems, solubility enhancement, and patient-centric dosing, serving pharmaceutical companies requiring oral solid dose formulation and commercial-scale production. Manufacturing capabilities span clinical trial materials, technology transfer, commercial-scale production, and packaging with serialization, supported by seven facilities across the United States and Italy.

Product overview

Adare Pharma Solutions is a global technology-driven Contract Development and Manufacturing Organization (CDMO) providing end-to-end integrated services from product development through commercial manufacturing and packaging, focused on oral dosage forms for the pharmaceutical industry. The company's portfolio consists of multiple proprietary technology platforms including AdvaTab® (oral disintegration), Diffucaps® (controlled release), Diffutab® (sustained release), Microcaps® (taste masking), Minitabs™ (mini tablet system), Parvulet® (patient-centric dosing), Stratμm™ (injectable micro-encapsulation), Optimμm® (oral microcapsules), Unisun® (intratympanic delivery), Adaptdose™ (customized release), and Duragran™ (controlled release granules). These technologies are supported by specialized services including formulation development, analytical services, high potency handling, nitrosamine mitigation, 3D printing, and abuse-deterrent testing. Manufacturing capabilities span clinical trial materials, tech transfer, commercial-scale production, and packaging with serialization. The company operates seven facilities across the US and Europe and has developed and manufactured more than 65 products sold globally.

Differentiator

Problem solved

Functional benefit

Brands

• AdvaTab®: Oral disintegration technology that masks bitter drug taste and rapidly dissolves in the mouth without water
• Diffucaps®
• Diffutab®
• Microcaps®
• Minitabs™
• Optimμm®
• Parvulet®
• Stratμm®
• Unisun®
• Adaptdose™
• Duragran™
• Orbis Biosciences®
• Precision Particle Fabrication™
• 3D Screen Printing

Products and services

• AdvaTab® Orally disintegrating tablet technology that masks bitter drug taste and rapidly dissolves in the mouth without water, providing easy administration for pharmaceutical company clients developing patient-friendly oral dosage forms.
• Diffucaps® Drug delivery control technology that optimizes release profiles and enhances bioavailability through SS-SD solid dispersion and spray drying technologies that preserve a drug's amorphous form.
• Diffutab® Customized release technology for targeted drug delivery of high-dosage sustained release products designed for once-daily administration.
• Microcaps® Taste masking solution using precisely and uniformly coated individual drug particles to deliver smooth, pleasant mouthfeel with no aftertaste for pharmaceutical clients.
• Minitabs™ Mini tablet system combining the simplicity of tablet formulation with the flexibility of multiparticulate dosage forms and high drug-loading capability for controlled release applications.
• Parvulet® Patient-centric oral dosing solution ideal for pediatric and geriatric populations as well as patients with swallowing difficulties, supporting adherence in vulnerable patient groups.
• Stratμm™ Micro-encapsulation technology for precision injectable drug delivery that titrates drug release kinetics to enable novel injectable drug delivery products for long-acting injectables.
• Optimμm® Precision oral dose microcapsules allowing high drug loading suitable for taste masking, enteric coatings, and extended release oral applications for pharmaceutical clients.
• Unisun® Intratympanic delivery technology for delivering small molecules, peptides, monoclonal antibodies, proteins, and macromolecules for the treatment of otic disorders.
• Adaptdose™ Customized release technology platform providing formulation flexibility that can eliminate the need to reformulate a candidate after Phase I clinical trials.
• Duragran™ Process for creating controlled release beadlets and granules of uniform and narrow particle size range, supporting flexible dosing solutions.
• Orbis Biosciences® Technologies Patient-centered solution technologies for complex oral formulation challenges, including precision particle-based drug delivery approaches.
• Taste Masking Services Specialized CDMO service providing taste-masked products and alternative dosage forms with excellent mouthfeel to improve patient adherence and potentially extend product patent life for pharmaceutical clients.
• Modified Release Development Customized drug release platform providing technologies with a range of customized release profiles tailored to optimize therapeutic performance, improve efficacy, and enhance safety for pharmaceutical clients.
• Solubility Enhancement / Bioavailability Enhancement Solubility enhancement platform using proprietary activation systems to break down drug particles to a thermodynamically activated form, improving onset of action and reducing variability of absorption and food effects for poorly soluble compounds.
• Patient-Centric Dosing Solutions State-changing technologies including orally disintegrating tablets that increase patient adherence and ensure accurate dosing for pediatric and geriatric patients and those with swallowing difficulties.
• Formulation Development Formulation development capabilities focused on taste masking, customized release, and patient-centered state-changing dosage forms for pharmaceutical client programs.
• Analytical Services Comprehensive analytical testing services and stability studies across various temperature ranges to support pharmaceutical client drug development programs.
• Pediatric Formulations Development Specialized formulation development services for pediatric patient populations with unique dosing needs, supporting client pediatric drug development programs.
• Clinical Trial Materials Manufacturing Flexible clinical trial material manufacturing services with GMP and Non-GMP capabilities supporting pharmaceutical client product development through clinical phases.
• Technology Transfer Services Technology transfer services with a dedicated transfer team to facilitate smooth project transfer and market entry for pharmaceutical client programs.
• Commercial-Scale Manufacturing Commercial-scale oral solid dose manufacturing with flexible and scalable capabilities to ensure project success on time and on budget for pharmaceutical clients.
• Commercial Packaging Services Full range of high-speed filling and packaging solutions for commercial and clinical supplies at FDA-registered packaging facilities, including serialization and DEA controlled substance packaging.
• High Potency Compound Handling High potency compound handling capabilities for safe processing of potent pharmaceutical compounds in pharmaceutical client manufacturing programs.
• Nitrosamine Mitigation Services Specialized service focused on nitrosamine risk assessment and mitigation strategies for pharmaceutical client products to address regulatory concerns.
• Abuse-Deterrent Testing Services Testing services for abuse-deterrent formulations (Category 1) to support pharmaceutical client opioid and controlled substance product development.
• Small-Scale Non-GMP Laboratory Services Non-GMP development scale laboratory services for early-stage pharmaceutical client product development and testing.
• Precision Particle Fabrication™ Services Specialized technology service for precision particle fabrication in pharmaceutical client drug development programs and advanced drug delivery applications.
• 3D Screen Printing Services Specialized service applying 3D printing technology for pharmaceutical manufacturing, enabling innovative dosage form design for pharmaceutical clients.

Quantifiable outcome

• Over 65 products launched for the global market
• +1 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature13 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Achieve Life SciencescoreStrategic or Co-development Partner · 24 March 2026Partnership for cytisinicline manufacturing - Adare provides supply chain redundancy and U.S.-based manufacturing capability for Achieve Life Sciences' nicotine dependence drug. Technology transfer was completed in April 2026.
• RS ItaliaminorImplementation/ SI/ Consulting Partner · 19 January 2026Partnership with RS Italia transformed Adare's MRO (Maintenance, Repair, and Operations) procurement, achieving up to 30% savings and supplier rationalization through digitalization and value-added services.
• Frontida BioPharmcoreStrategic or Co-development Partner · 1 December 2021Adare Pharma Solutions acquired Frontida BioPharm, a vertically integrated CDMO specializing in oral formulations, to expand its service offerings and global manufacturing footprint. The combined company offers enhanced capabilities including high potency compound handling, taste masking, controlled release, and bioavailability enhancement.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Thermo Fisher Scientific (Patheon): Thermo Fisher's Patheon business is a broad incumbent CDMO offering oral solid dose manufacturing among many other services; it competes with Adare on pharmaceutical client RFPs but is several times larger and operates across biologics, sterile fill-finish, and clinical services as well.
• Capsugel (Lonza): Lonza's Capsugel business offers oral dosage form development and commercial manufacturing services globally, overlapping with Adare's core CDMO offering but operating within a much larger diversified CDMO portfolio.

Direct peers

• Piramal Pharma Solutions: Piramal Pharma Solutions is a global CDMO offering drug substance and drug product services including oral solid dosage form development, directly comparable to Adare's end-to-end small-molecule CDMO offering.
• Cambrex: Cambrex is a small-molecule CDMO offering API and finished dosage form development and manufacturing services; it is comparable to Adare in serving pharma clients needing integrated small-molecule drug substance and drug product solutions.
• Aenova Group: Aenova is a European-headquartered CDMO specializing in solid dosage forms (tablets, capsules, pellets), comparable to Adare in serving pharma clients across the full development-to-commercial lifecycle and operating EU GMP-registered facilities.
• Recipharm: Recipharm is a global CDMO with strong capabilities in oral solid dosage forms and development services for pharmaceutical clients, directly comparable to Adare in business model and target customer base across development and commercial supply.
• Catalent: Catalent is one of the largest global CDMOs and a direct peer to Adare, with deep capabilities in oral solid dose formulation and manufacturing including taste-masking, modified release, and bioavailability enhancement, serving similar pharmaceutical and specialty pharma customers.

Emerging players

• Alcami Corporation: Alcami is a mid-sized US CDMO offering development and manufacturing services including oral solid dose, comparable to Adare in business model but with a smaller facility footprint and narrower technology platform range.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/adarepharmasolutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adare Pharmaceuticals